speedy/RINGO cell cycle regulator family member E4Genealiases: []
Q-omics provides the consensus-scored SPDYE4 profile across patient tissues and cancer cell-line models. SPDYE4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SPDYE4 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, SPDYE4 RNA expression shows 9,953 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, THCA, and THYM as cancer lineages where SPDYE4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPDYE4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPDYE4 survival associations across molecular data types. SPDYE4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPDYE4 RNA expression–survival associations across cancer types. High SPDYE4 expression shows unfavorable associations in MESO and COAD, but favorable associations in PAAD, HNSC, SKCM and CESC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for SPDYE4 RNA expression.
This table summarizes SPDYE4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SPDYE4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPDYE4 shows lower tumor expression in THCA, COAD, LUSC, READ, UCEC and LIHC. The THCA box plot shows higher SPDYE4 RNA expression in normal versus tumor tissue (log2 FC = −0.147, t-test p < 0.001).
This table shows molecular features associated with SPDYE4 in patient tissues and cancer cell lines. In patient samples, SPDYE4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SPDYE4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
